Vitamin D receptor agonists target static, dynamic, and inflammatory components of benign prostatic hyperplasia: Annals of the New York Academy of Sciences

Luciano Adorini, Giuseppe Penna, Benedetta Fibbi, Mario Maggi

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

The bioactive form of vitamin D, 1,25-dihydroxyvitamin D3, is a secosteroid hormone that binds to the vitamin D receptor (VDR), a member of the nuclear receptor superfamily, and modulates a variety of biological functions. The VDR is expressed by most cell types, including cells of the urogenital system, such as prostate and bladder cells. In particular, the prostate is a target organ of VDR agonists and represents an extrarenal synthesis site of 1,25-dihydroxyvitamin D3. We have analyzed the capacity of VDR agonists to treat benign prostatic hyperplasia (BPH), a complex syndrome characterized by a static component related to prostate overgrowth, a dynamic component responsible for urinary irritative symptoms, and an inflammatory component. Data reviewed here demonstrate that VDR agonists, and notably elocalcitol, reduce the static component of BPH by inhibiting the activity of intraprostatic growth factors downstream of the androgen receptor, the dynamic component by targeting the RhoA/ROCK pathway in prostate and bladder cells, and the inflammatory component by targeting the NF-κB pathway.

Original languageEnglish
Title of host publicationAnnals of the New York Academy of Sciences
Pages146-152
Number of pages7
Volume1193
DOIs
Publication statusPublished - Apr 2010

Publication series

NameAnnals of the New York Academy of Sciences
Volume1193
ISSN (Print)00778923
ISSN (Electronic)17496632

Keywords

  • Antigen-presenting cells
  • Benign prostatic hyperplasia
  • Chronic prostatic inflammation
  • Chronic prostatitis/chronic pelvic pain syndrome

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Vitamin D receptor agonists target static, dynamic, and inflammatory components of benign prostatic hyperplasia: Annals of the New York Academy of Sciences'. Together they form a unique fingerprint.

Cite this